Akin Advised RP Management on its $1.1 Billion Sale to Royal Pharma
Contact:
(New York and Los Angeles) – Akin advised RP Management, LLC in connection with its sale to Royal Pharma plc. for approximately $1.1 billion in cash, stock and assumed debt. The deal is expected to close in the second half of 2025, subject to shareholder approval and other customary closing conditions.
The Akin team was led by partners Stuart Leblang, David Antheil and Eric Wexler.
For further information on the transaction, please click here.
Akin is a leading international law firm with more than 900 lawyers in offices throughout the United States, Europe, Asia and the Middle East.
# # #
People Mentioned in This News
© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.